LUCY Quote, Financials, Valuation and Earnings

The Cooper Companies has a net margin of -307.83% compared to Innovative Eyewear's net margin of 10.81%. Innovative Eyewear's return on equity of -105.44% beat The Cooper Companies's return on equity of 5.24%.

Innovative Eyewear has a consensus price target of $9.00, signalling upside risk potential of 282.98%. On the other hand The Cooper Companies has an analysts' consensus of $106.98 which suggests that it could grow by 38.11%. Given that Innovative Eyewear has higher upside potential than The Cooper Companies, analysts believe Innovative Eyewear is more attractive than The Cooper Companies.

Innovative Eyewear has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.692%.

Innovative Eyewear has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Innovative Eyewear pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

Innovative Eyewear quarterly revenues are $690.7K, which are smaller than The Cooper Companies quarterly revenues of $964.7M. Innovative Eyewear's net income of -$2.1M is lower than The Cooper Companies's net income of $104.3M. Notably, Innovative Eyewear's price-to-earnings ratio is -- while The Cooper Companies's PE ratio is 37.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovative Eyewear is 2.11x versus 3.96x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

OrthoPediatrics has a net margin of -307.83% compared to Innovative Eyewear's net margin of -30.51%. Innovative Eyewear's return on equity of -105.44% beat OrthoPediatrics's return on equity of -10.25%.

Innovative Eyewear has a consensus price target of $9.00, signalling upside risk potential of 282.98%. On the other hand OrthoPediatrics has an analysts' consensus of $38.43 which suggests that it could grow by 81.61%. Given that Innovative Eyewear has higher upside potential than OrthoPediatrics, analysts believe Innovative Eyewear is more attractive than OrthoPediatrics.

Innovative Eyewear has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.642%.

Innovative Eyewear has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovative Eyewear pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

Innovative Eyewear quarterly revenues are $690.7K, which are smaller than OrthoPediatrics quarterly revenues of $52.7M. Innovative Eyewear's net income of -$2.1M is higher than OrthoPediatrics's net income of -$16.1M. Notably, Innovative Eyewear's price-to-earnings ratio is -- while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovative Eyewear is 2.11x versus 2.39x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -307.83% compared to Innovative Eyewear's net margin of -27.95%. Innovative Eyewear's return on equity of -105.44% beat NexGel's return on equity of -63.18%.

Innovative Eyewear has a consensus price target of $9.00, signalling upside risk potential of 282.98%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 136.22%. Given that Innovative Eyewear has higher upside potential than NexGel, analysts believe Innovative Eyewear is more attractive than NexGel.

Innovative Eyewear has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innovative Eyewear has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovative Eyewear pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Innovative Eyewear quarterly revenues are $690.7K, which are smaller than NexGel quarterly revenues of $3M. Innovative Eyewear's net income of -$2.1M is lower than NexGel's net income of -$850K. Notably, Innovative Eyewear's price-to-earnings ratio is -- while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovative Eyewear is 2.11x versus 1.90x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -307.83% compared to Innovative Eyewear's net margin of -69.92%. Innovative Eyewear's return on equity of -105.44% beat Staar Surgical's return on equity of -5.02%.

Innovative Eyewear has a consensus price target of $9.00, signalling upside risk potential of 282.98%. On the other hand Staar Surgical has an analysts' consensus of $18.67 which suggests that it could grow by 11.18%. Given that Innovative Eyewear has higher upside potential than Staar Surgical, analysts believe Innovative Eyewear is more attractive than Staar Surgical.

Innovative Eyewear has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.297%.

Innovative Eyewear has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovative Eyewear pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

Innovative Eyewear quarterly revenues are $690.7K, which are smaller than Staar Surgical quarterly revenues of $49M. Innovative Eyewear's net income of -$2.1M is higher than Staar Surgical's net income of -$34.2M. Notably, Innovative Eyewear's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovative Eyewear is 2.11x versus 2.64x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.